Cancer Research

The biological mystery of why two women with the exact same genetic mutation face drastically different health outcomes remains one of the most pressing questions in modern oncology. While the presence of a BRCA1 mutation is often viewed as a definitive roadmap for a patient’s future, the actual

The landscape of thoracic oncology is undergoing a seismic shift as precision medicine transforms what were once considered terminal diagnoses into manageable chronic conditions for many patients. For individuals battling advanced non-small cell lung cancer (NSCLC) characterized by RET gene

Ivan Kairatov is a leading biopharma expert with a deep specialization in the metabolic pathways that govern cancer progression and therapeutic resistance. With years of experience in research and development, Kairatov has focused on how innovation in the industry can sometimes clash with

The landscape of modern oncology is currently witnessing a tectonic shift as clinical researchers increasingly abandon the cumbersome laboratory-based cell modification protocols that have defined the last decade. For several years, the medical community viewed Chimeric Antigen Receptor (CAR)

The landscape of oncology is shifting as researchers uncover ways to bypass the treatment resistance that typically limits the life expectancy of patients with advanced non-small cell lung cancer. In a field where standard therapies often provide only a few months of additional survival for those

Ivan Kairatov stands at the intersection of biopharmaceutical innovation and clinical technology, bringing years of expertise in research and development to the forefront of oncology care. His work focuses on bridging the gap between raw medical data and actionable clinical insights, particularly